Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

38.71 +0.54 (+1.41%)
Streaming Delayed Price Updated: 10:03 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
 
Via Benzinga
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks
Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover. 
Via Stocktwits
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
 
Via Benzinga
Looking Into Viking Therapeutics's Recent Short Interest
 
Via Benzinga
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts
This is a high-risk, high-reward stock. 
Via The Motley Fool
Why Viking Therapeutics Stock Plummeted by 24% in December
Via The Motley Fool
Should You Buy the Dip on This High-Flying Stock?
Via The Motley Fool
StoryTrading's Secrets To January Gains - Don’t Miss These Picks
As we usher in the new year, market dynamics continue to be shaped by a blend of tax-deferral selling, the January effect, and macro uncertainties. 
Via Talk Markets
Topics Stocks / Equities
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for. 
Via The Motley Fool
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
From Powell To Profits: Strategic Stock Picks Amid Market Uncertainty
Yesterday's market movement aligned perfectly with expectations, as the FOMC meeting drove significant volatility. 
Via Talk Markets
Topics Stocks / Equities
What's Going On With Viking Therapeutics Stock On Wednesday?
Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for future growth. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Via The Motley Fool
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.